HCWB Stock Overview
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HCW Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.62 |
| 52 Week High | US$2.32 |
| 52 Week Low | US$0.91 |
| Beta | 0.98 |
| 1 Month Change | -8.47% |
| 3 Month Change | 40.97% |
| 1 Year Change | 10.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.29% |
Recent News & Updates
Shareholder Returns
| HCWB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.2% | -5.0% | -3.5% |
| 1Y | 11.0% | -1.7% | 20.2% |
Return vs Industry: HCWB exceeded the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: HCWB underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| HCWB volatility | |
|---|---|
| HCWB Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HCWB's share price has been volatile over the past 3 months.
Volatility Over Time: HCWB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 45 | Hing Wong | www.hcwbiologics.com |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment.
HCW Biologics Inc. Fundamentals Summary
| HCWB fundamental statistics | |
|---|---|
| Market cap | US$59.95m |
| Earnings (TTM) | -US$24.99m |
| Revenue (TTM) | US$2.84m |
21.6x
P/S Ratio-2.5x
P/E RatioIs HCWB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCWB income statement (TTM) | |
|---|---|
| Revenue | US$2.84m |
| Cost of Revenue | US$7.53m |
| Gross Profit | -US$4.69m |
| Other Expenses | US$20.30m |
| Earnings | -US$24.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | -165.02% |
| Net Profit Margin | -879.52% |
| Debt/Equity Ratio | 47.7% |
How did HCWB perform over the long term?
See historical performance and comparison